Abstracts

Effect of Remdesivir on Post-COVID Conditions Among Individuals Hospitalized With COVID-19 by Age

Background: Post-COVID conditions (PCC), or long COVID, are part of a persistent, multisystemic syndrome occurring after COVID-19. The effect of the antiviral remdesivir (RDV) on subsequent outcomes associated with PCC is unknown. Of particular interest are RDV’s effects stratified by age, which is a predictor of outcomes in patients hospitalized with COVID-19. Methods: The HealthVerity…

48-Week Outcomes After Programmatic Transition to Dolutegravir in South Africa

Background: South Africa introduced tenofovir/lamivudine/dolutegravir (TLD) as the preferred first-line antiretroviral therapy (ART) regimen in 2019. Few data are available from individuals who transitioned from efavirenz (EFV)-based ART to TLD in rural public sector clinics in South Africa. Our objective was to evaluate viral suppression and regimen tolerability for individuals who were transitioned to TLD…

ACTG 5381: Virologic and Resistance Outcomes After Switch to TLD for Failing 1st- or 2nd-Line ART

Background: Most countries recommend tenofovir-lamivudine-dolutegravir (TLD) for individuals starting antiretroviral therapy (ART) or switching from suppressive 1st-line NNRTI- or 2nd-line PI-based ART but country guidelines have been more variable about using TLD for those with unsuppressed (plasma HIV-1 RNA>1000 c/ml) viral load (VL) on ART. We report virologic and resistance outcomes for unsuppressed individuals switching…

Global Trends in CD4 Count Measurement and Prevalence of CD4

Background: Since the ‘Treat-All’ era, people with HIV (PWH) start antiretroviral therapy (ART) regardless of CD4 count; consequently, CD4 measurement at ART initiation is declining in many countries. However, CD4 counts are still necessary to identify people with advanced HIV disease, to monitor and evaluate ART programs, and to inform epidemiological models. We described CD4…

Immunogenicity of Tixagevimab/Cilgavimab for COVID-19 in Immunocompromised Children and Adolescents

Background: COVID-19 vaccination prevents severe manifestations, hospitalization, and mortality in healthy patients. Immunocompromised populations have a higher risk of complications, but poorer responses to vaccination. Long-acting monoclonal antibodies Tixagevimab/Cilgavimab effectively prevented COVID-19 and improved clinical outcomes when administered early after infection. They were approved for emergency use in ≥40 kg and ≥12 years old immunocompromised…

Real-World Virologic Outcomes of Cabotegravir/Rilpivirine in Patients With Elevated Body Mass Index

Background: Injectable cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting antiretroviral (ARV) regimen approved in persons with HIV with sustained virologic suppression (HIV RNA 30 kg/m2 alone was not predictive of confirmed virologic failure; however, data are limited due to small sample sizes. The primary objective of this study is to determine the…